AstraZeneca and Amgen drug Tezspire met the goals of a Phase 3 test in eosinophilic esophagitis (EoE), a chronic disorder whose only approved biologic therapy is Sanofi’s Dupixent. An approval for Tezspire in EoE would be its third indication, bolstering sales of the blockbuster product.

The post AstraZeneca, Amgen Drug Moves Closer to Competing With Dupixent in a New Indication appeared first on MedCity News.